![Exhibitor - Amgen - Virtual Exhibit Hall - Hematology Review 2021 | Mayo Clinic School of Continuous Professional Development Exhibitor - Amgen - Virtual Exhibit Hall - Hematology Review 2021 | Mayo Clinic School of Continuous Professional Development](https://ce.mayo.edu/sites/default/files/Amgen%20Logo%202017.png)
Exhibitor - Amgen - Virtual Exhibit Hall - Hematology Review 2021 | Mayo Clinic School of Continuous Professional Development
![Physicochemical stability of carfilzomib (Kyprolis®) containing solutions in glass vials, ready-to-administer plastic syringes and infusion bags over a 28-day storage period - Sun Hee Kim, Irene Krämer, 2019 Physicochemical stability of carfilzomib (Kyprolis®) containing solutions in glass vials, ready-to-administer plastic syringes and infusion bags over a 28-day storage period - Sun Hee Kim, Irene Krämer, 2019](https://journals.sagepub.com/cms/10.1177/1078155217735881/asset/images/large/10.1177_1078155217735881-fig3.jpeg)
Physicochemical stability of carfilzomib (Kyprolis®) containing solutions in glass vials, ready-to-administer plastic syringes and infusion bags over a 28-day storage period - Sun Hee Kim, Irene Krämer, 2019
![Proteasome Inhibitors for Treating Multiple Myeloma: R&D Status | Huateng Pharma | Pharmaceutical chemical reagents, PEG derivatives Proteasome Inhibitors for Treating Multiple Myeloma: R&D Status | Huateng Pharma | Pharmaceutical chemical reagents, PEG derivatives](https://en.huatengsci.com/usr/uploads/3/202006/Oprozomib.jpg)
Proteasome Inhibitors for Treating Multiple Myeloma: R&D Status | Huateng Pharma | Pharmaceutical chemical reagents, PEG derivatives
![NICE recommends Amgen's carfilzomib with dexamethasone for RMM treatment - Pharmaceutical Technology NICE recommends Amgen's carfilzomib with dexamethasone for RMM treatment - Pharmaceutical Technology](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2017/09/main-1196.jpg)
NICE recommends Amgen's carfilzomib with dexamethasone for RMM treatment - Pharmaceutical Technology
pan-Canadian Oncology Drug Review Final Clinical Guidance Report Carfilzomib (Kyprolis) for Multiple Myeloma
![Physicochemical stability of carfilzomib (Kyprolis®) containing solutions in glass vials, ready-to-administer plastic syringes and infusion bags over a 28-day storage period - Sun Hee Kim, Irene Krämer, 2019 Physicochemical stability of carfilzomib (Kyprolis®) containing solutions in glass vials, ready-to-administer plastic syringes and infusion bags over a 28-day storage period - Sun Hee Kim, Irene Krämer, 2019](https://journals.sagepub.com/cms/10.1177/1078155217735881/asset/images/large/10.1177_1078155217735881-fig5.jpeg)
Physicochemical stability of carfilzomib (Kyprolis®) containing solutions in glass vials, ready-to-administer plastic syringes and infusion bags over a 28-day storage period - Sun Hee Kim, Irene Krämer, 2019
![KRd Plus Lenalidomide Maintenance Yielded Positive MRD- CRs and May Delay End-Organ Disease in High-Risk Smoldering Myeloma KRd Plus Lenalidomide Maintenance Yielded Positive MRD- CRs and May Delay End-Organ Disease in High-Risk Smoldering Myeloma](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bfb3164ac05cb66a83a462f40af8011be1a45819-1600x900.jpg?fit=crop&auto=format)
KRd Plus Lenalidomide Maintenance Yielded Positive MRD- CRs and May Delay End-Organ Disease in High-Risk Smoldering Myeloma
![Amgen gets cosier with Dr. Reddy's, adding three marketed drugs to Indian partnership | Fierce Pharma Amgen gets cosier with Dr. Reddy's, adding three marketed drugs to Indian partnership | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/2016-09/Dr_Reddys_0.jpg?VersionId=.wjsaamgn6iPw9IRjXTzDxypyqKtXUiq)